Teva Secures FDA Approval for Two Asthma Combination Products

Teva Pharmaceuticals received FDA approvals for two asthma combination products to treat adolescents and adults.

One of the approved therapies, AirDuo RespiClick, is similar to GlaxoSmithKline’s Advair inhaler and contains the same active ingredient as the top-selling therapy. AirDuo is a fixed dose combination product indicated for the treatment of patients 12 and older.

The second approved therapy, ArmonAir RespiClick, contains the same active ingredient as GSK’s Flovent. Both AirDuo and ArmonAir are breath-activated, multi-dose dry powder inhalers which can be used with other approved drugs.